Anders Wallin

Q: What Schools Are Affiliated With Anders Wallin

Anders Wallin is affiliated with the following schools: Sahlgrenska Academy, Norwegian University of Science and Technology, University of Gothenburg

Anders Wallin's AcademicInfluence.com Rankings

Anders Wallin

Computer Science

#6114

World Rank

#6445

Historical Rank

Machine Learning

#1878

World Rank

#1903

Historical Rank

Artificial Intelligence

#2125

World Rank

#2161

Historical Rank

Database

#3227

World Rank

#3363

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Anders Wallin's Degrees

Masters Computer Science Norwegian University of Science and Technology

Similar Degrees You Can Earn

Best Online Master's in Computer Science

Why Is Anders Wallin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Anders Wallin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT (2001) (1575)
National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards (2006) (1436)
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. (2009) (1139)
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
Subcortical ischaemic vascular dementia (2002) (967)
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? (1995) (749)
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. (1999) (640)
Research criteria for subcortical vascular dementia in clinical trials. (2000) (631)
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. (2005) (440)
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. (2001) (418)
Impact of Age-Related Cerebral White Matter Changes on the Transition to Disability – The LADIS Study: Rationale, Design and Methodology (2004) (412)
Association of gait and balance disorders with age-related white matter changes (2008) (402)
Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort (2009) (384)
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. (2019) (379)
Vascular dysfunction—The disregarded partner of Alzheimer's disease (2019) (361)
Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma (2000) (332)
Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization (2008) (320)
Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia (2002) (312)
Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia (1999) (312)
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. (2015) (285)
White Matter Changes on CT and MRI: An Overview of Visual Rating Scales (1998) (283)
Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia (2004) (271)
The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? (2014) (258)
Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment (2010) (252)
Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid (2010) (248)
2001–2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease? (2011) (246)
CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging (2000) (239)
A population study on blood-brain barrier function in 85-year-olds (1998) (238)
Both total and phosphorylated tau are increased in Alzheimer's disease (2001) (235)
Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. (2007) (216)
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias (2003) (212)
Treatment of Alzheimer’s Disease with Clioquinol (2001) (210)
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition (2005) (205)
Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss? (2009) (205)
Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study (2018) (204)
SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease (2014) (202)
Consensus guidelines for lumbar puncture in patients with neurological diseases (2017) (197)
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment (2009) (185)
Age, Hypertension, and Lacunar Stroke Are the Major Determinants of the Severity of Age-Related White Matter Changes (2006) (183)
Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS Study (2009) (182)
White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities (2019) (182)
Neurofilament protein in cerebrospinal fluid: A marker of white matter changes (2001) (181)
White‐matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors (1991) (180)
Blood‐brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors (1990) (180)
Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment (2007) (179)
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD (2000) (173)
Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study (2016) (170)
Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. (1993) (169)
CSF amyloid β42 and tau levels correlate with AIDS dementia complex (2005) (168)
Age and diagnostic performance of Alzheimer disease CSF biomarkers (2012) (163)
Consensus statement for diagnosis of subcortical small vessel disease (2016) (163)
Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study (2007) (159)
Neurofilament protein levels in CSF are increased in dementia (1999) (156)
The neurochemistry of vascular dementia. (1994) (152)
White matter hyperintensities rather than lacunar infarcts are associated with depressive symptoms in older people: the LADIS study. (2006) (152)
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI (2007) (145)
Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. (2011) (143)
Further molecular and clinical delineation of co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes (2010) (143)
Low frequency of post‐lumbar puncture headache in demented patients (1993) (142)
The Vascular Impairment of Cognition Classification Consensus Study (2017) (140)
White matter lesion progression (2004) (138)
Deep frontal and periventricular age related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls: cross sectional results from the LADIS study (2009) (137)
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. (2007) (136)
A double‐blind evaluation of electroconvulsive therapy in Parkinson's disease with “on‐off” phenomena (1987) (134)
White matter changes and late-life depressive symptoms (2007) (132)
Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms (2002) (132)
Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease (2013) (130)
Brain atrophy accelerates cognitive decline in cerebral small vessel disease (2012) (129)
White matter changes and diabetes predict cognitive decline in the elderly (2010) (126)
An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid (2006) (124)
White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. (1998) (123)
Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study (2009) (123)
Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. (2008) (120)
Low blood pressure and blood glucose levels in Alzheimer's disease Evidence for a hypometabolic disorder? (1993) (117)
Two-year outcome of MCI subtypes and aetiologies in the Göteborg MCI study (2009) (117)
Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
Physical Activity Prevents Progression for Cognitive Impairment and Vascular Dementia: Results From the LADIS (Leukoaraiosis and Disability) Study (2012) (115)
Cognitive impairment in patients with stress-related exhaustion (2013) (114)
Aggrecan and chondroitin-6-sulfate abnormalities in schizophrenia and bipolar disorder: a postmortem study on the amygdala (2015) (111)
The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. (2001) (111)
Limitations of Clincal Criteria for the Diagnosis of Vascular Dementia in Clinical Trials: Is a Focus on Subcortical Vascular Dementia a Solution? (2000) (110)
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. (2007) (110)
Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility (2011) (110)
No association between the α2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression (2000) (107)
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. (2005) (107)
Cerebrospinal fluid biomarkers of white matter lesions – cross‐sectional results from the LADIS study (2010) (105)
The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological Process (2001) (104)
Inflammatory biomarkers in Alzheimer's disease plasma (2019) (104)
Relationship between periventricular and deep white matter lesions and depressive symptoms in older people. The LADIS Study (2006) (102)
Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? (2001) (102)
Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study (2010) (102)
Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia (1996) (101)
Cardiovascular and cognitive fitness at age 18 and risk of early-onset dementia. (2014) (100)
Treatment with Simvastatin in Patients with Alzheimer’s Disease Lowers Both α- and β-Cleaved Amyloid Precursor Protein (2003) (99)
Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. (2013) (99)
The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer’s Disease (2005) (98)
Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. (2009) (97)
Blood brain barrier function in vascular dementia (1990) (96)
White Matter Lesion Progression in LADIS: Frequency, Clinical Effects, and Sample Size Calculations (2012) (94)
MRI-Defined Subcortical Ischemic Vascular Disease: Baseline Clinical and Neuropsychological Findings (2009) (94)
Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting (2006) (93)
Leukoaraiosis Predicts Hidden Global Functioning Impairment in Nondisabled Older People: The LADIS (Leukoaraiosis and Disability in the Elderly) Study (2006) (91)
Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: The Göteborg MCI study (2008) (90)
Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial (2000) (90)
Cognitive profiles of mild cognitive impairment with and without vascular disease. (2007) (89)
White matter imaging changes in subjective and mild cognitive impairment (2012) (88)
Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method (2011) (88)
Decreased myelin lipids in Alzheimer's disease and vascular dementia (1989) (87)
Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke (2014) (87)
Symptoms, Vascular Risk Factors and Blood-Brain Barrier Function in Relation to CT White-Matter Changes in Dementia (2000) (86)
The Gothenburg MCI study: Design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up (2016) (86)
Neurotransmitter deficits in a non‐multi‐infarct category of vascular dementia (1989) (85)
Role of white matter lesions in cognitive impairment of vascular origin. (1999) (85)
White matter low attenuation on computed tomography in Alzheimer's disease and vascular dementia – diagnostic and pathogenetic aspects (1989) (84)
Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease (2011) (83)
Local and systemic GM‐CSF increase in Alzheimer's disease and vascular dementia (2001) (83)
Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment (2005) (83)
Urinary Complaints in Nondisabled Elderly People with Age‐Related White Matter Changes: The Leukoaraiosis And DISability (LADIS) Study (2008) (82)
Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. (1993) (82)
Development of a Neuropsychological Battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): Experience and Baseline Data (2006) (82)
Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study (2012) (82)
Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease2 (2018) (81)
Global Burden of Small Vessel Disease–Related Brain Changes on MRI Predicts Cognitive and Functional Decline (2019) (81)
Protein Analysis in Cerebrospinal Fluid (1993) (80)
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. (2014) (79)
Association of complement factor H Y402H gene polymorphism with Alzheimer's disease (2008) (78)
Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E ε4 Frequency, but No Tau Gene Mutations (2001) (78)
Multimodal Markers of Inflammation in the Subcortical Ischemic Vascular Disease Type of Vascular Cognitive Impairment (2014) (77)
Antibodies in cerebrospinal fluid of some Alzheimer disease patients recognize cholinergic neurons in the rat central nervous system. (1987) (77)
Gangliosides in cerebrospinal fluid in 'probable Alzheimer's disease'. (1991) (76)
Decreased monoamine metabolites in frontotemporal dementia and Alzheimer’s disease (1998) (75)
Subtypes of vascular dementia. (1999) (75)
Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer’s Disease Dementia in Individuals With Mild Cognitive Impairment (2017) (75)
Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. (2012) (74)
Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. (2011) (74)
Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract (2010) (73)
Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. (2002) (72)
Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report (2017) (72)
White matter hyperintensities and depression—preliminary results from the LADIS study (2005) (71)
Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18–88 years of age (1993) (71)
Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study (2013) (69)
The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia (2000) (69)
Altered blood‐brain‐barrier function in Alzheimer's disease? (1994) (68)
Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease (2013) (67)
Diffusion changes predict cognitive and functional outcome: The LADIS study (2013) (67)
A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia. (2013) (67)
Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. (1996) (66)
Pathogenetic basis of vascular dementia. (1991) (66)
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics (2018) (66)
Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. (2009) (66)
Frontotemporal Dementia Can Be Distinguished from Alzheimer’s Disease and Subcortical White Matter Dementia by an Anterior-to-Posterior rCBF-SPET Ratio (2000) (65)
Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF (1998) (65)
Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. (2013) (64)
Imaging biomarkers of dementia: recommended visual rating scales with teaching cases (2016) (63)
Clinical Heterogeneity of Probable Alzheimer's Disease (1992) (63)
Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change - The LADIS Study (2013) (63)
Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. (1996) (62)
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis (2009) (62)
No neurochemical evidence for brain injury caused by heading in soccer (2007) (62)
Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease (1992) (61)
The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. (1996) (61)
Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. (2011) (61)
Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia (1992) (58)
A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort (2019) (57)
Hyperactivity in the hypothalamic-pituitary-adrenal axis in demented patients with delirium (2001) (57)
Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases (2010) (56)
Classification and Subtypes of Vascular Dementia (2003) (55)
Heterogeneity of Vascular Dementia: Mechanisms and Subgroups (1993) (55)
Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia (2001) (55)
Apathy is a prominent neuropsychiatric feature of radiological white‐matter changes in patients with dementia (2009) (54)
Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study (2015) (53)
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort (2019) (53)
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. (2003) (51)
Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. (2011) (51)
VIP-sensitive adenylate cyclase, guanylate cyclase, muscarinic receptors, choline acetyltransferase and acetylcholinesterase, in brain tissue afflicted by alzheimer's disease/senile dementia of the Alzheimer type (1988) (51)
Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease (2013) (51)
Cross‐national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO‐HARPID) (2004) (50)
Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI (2008) (50)
Delirium in dementia (1998) (49)
Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. (1997) (49)
MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study (2018) (48)
Cognitive Profiles of Incipient Dementia in the Goteborg MCI Study (2010) (48)
Tacrine and rate of progression in Alzheimer's disease – relation to ApoE allele genotype (2001) (48)
Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes (2007) (47)
Presence of parieto‐temporal symptomatology distinguishes early and late onset Alzheimer's disease (1991) (47)
Neuron specific enolase in cerebrospinal fluid: A biochemical marker for neuronal degeneration in dementia disorders? (1994) (47)
Associations between white matter lesions, cerebrovascular risk factors, and low CSF Aβ42 (2006) (47)
Subcortical Vascular Dementia as a Specific Target for Clinical Trials (2000) (46)
Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid (1993) (46)
Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment (2009) (46)
Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study (2012) (45)
Increased Saliva Cortisol Awakening Response in Patients with Mild Cognitive Impairment (2007) (45)
Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease? (1995) (45)
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment (2009) (44)
Alzheimer’s disease—subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies (2016) (44)
Cross-national comparisons of the Cambridge Cognitive Examination-revised: the CAMCOG-R: results from the European Harmonization Project for Instruments in Dementia. (2003) (43)
Subcortical symptoms predominate in vascular dementia (1991) (43)
High White Matter Lesion Load Is Associated with Hippocampal Atrophy in Mild Cognitive Impairment (2011) (42)
No neurochemical evidence of brain injury after blast overpressure by repeated explosions or firing heavy weapons (2011) (42)
Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease (2013) (42)
Cystatin C in cerebrospinal fluid and multiple sclerosis (2007) (42)
Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study (2017) (42)
Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study. (2015) (41)
Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia (1995) (40)
White Matter Lesion Assessment in Patients with Cognitive Impairment and Healthy Controls: Reliability Comparisons between Visual Rating, a Manual, and an Automatic Volumetrical MRI Method—The Gothenburg MCI Study (2013) (40)
Diagnosis of dementias using partial least squares discriminant analysis. (1995) (40)
The Overlap between Alzheimer’s Disease and Vascular Dementia: The Role of White Matter Changes (1998) (40)
Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia (2003) (40)
Monoamine Metabolites in Cerebrospinal Fluid and Behavioral Ratings in Patients with Early and Late Onset of Alzheimer Dementia (1989) (39)
Ubiquitin in Cerebrospinal Fluid in Alzheimer's Disease and Vascular Dementia (1994) (39)
Parenteral administration of GM1 ganglioside to presenile Alzheimer patients (1990) (39)
Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype. (1999) (39)
Regulation of the Hypothalamic‐Pituitary‐Adrenal Axis in Dementia Disorders (1994) (38)
Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion‐weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the elderly) study (2009) (38)
The clinical diagnosis of vascular dementia. (1994) (37)
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease (2014) (37)
Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease (2011) (36)
Thyroid Hormones Are Associated with Poorer Cognition in Mild Cognitive Impairment (2010) (36)
High frequency of cognitive dysfunction before stroke among older people (2011) (36)
Cerebrospinal fluid biomarkers mirror rate of cognitive decline. (2013) (36)
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay (2019) (35)
Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study (2013) (34)
Formulas for the quantitation of intrathecal IgG production Their validity in the presence of blood-brain barrier damage and their utility in multiple sclerosis (1994) (34)
B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia (2009) (34)
Biomarkers in Relation to Cognitive Reserve in Patients with Mild Cognitive Impairment – Proof of Concept (2009) (34)
Immunoglobulin M in cerebrospinal fluid: reference values derived from 111 healthy individuals 18-88 years of age. (1996) (34)
Living with stable MCI: Experiences among 17 individuals evaluated at a memory clinic (2013) (34)
SYMPTOMATOLOGICAL CHARACTERISTICS DISTINGUISH BETWEEN FRONTOTEMPORAL DEMENTIA AND VASCULAR DEMENTIA WITH A DOMINANT FRONTAL LOBE SYNDROME (1997) (34)
Testicular-cancer survivors experience compromised language following chemotherapy: Findings in a Swedish population-based study 3–26 years after treatment (2012) (33)
Statin treatment and a disease-specific pattern of β-amyloid peptides in Alzheimer’s disease (2005) (33)
Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample (2017) (33)
Combination of Hippocampal Volume and Cerebrospinal Fluid Biomarkers Improves Predictive Value in Mild Cognitive Impairment (2010) (33)
The Cognitive Assessment Battery (CAB): a rapid test of cognitive domains (2011) (32)
7α-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid reflects the integrity of the blood-brain barrier (2014) (32)
Swedish consensus on dementia diseases. (1994) (32)
The Swedish National Adult Reading Test (NART-SWE): a test of premorbid IQ. (2008) (32)
Differences in cerebrospinal fluid gangliosides between “probable Alzheimer’s disease” and normal aging (1992) (32)
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4 (2013) (31)
Amyloid β1–40 Quantification in CSF: Comparison between Chromatographic and Immunochemical Methods (2007) (31)
Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. (2015) (30)
Clinical subgroups of the Alzheimer syndrome (1996) (30)
Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease (2016) (30)
Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. (2005) (29)
Working memory and attention are still impaired after three years in patients with stress-related exhaustion. (2017) (29)
Intrathecal Release of Nitric Oxide in Alzheimer’s Disease and Vascular Dementia (2000) (29)
Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy (2014) (28)
Depressive symptoms and white matter changes in patients with dementia (2006) (28)
Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset (2019) (28)
Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. (2011) (27)
Neuropsychological Predictors of Dementia in a Three-Year Follow-Up Period: Data from the LADIS Study (2010) (27)
High education may offer protection against tauopathy in patients with mild cognitive impairment. (2010) (27)
A novel ARC gene polymorphism is associated with reduced risk of Alzheimer’s disease (2012) (27)
Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. (2007) (27)
Hypothalamic monoamines and neuropeptides in dementia (1991) (26)
Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of Alzheimer’s disease (2019) (26)
A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease (2016) (26)
Vitamin B12 in CSF: reduced CSF/serum B12 ratio in demented men (1992) (25)
Antibodies recognizing cholinergic neurons and thyroglobuline are found in the cerebrospinal fluid of a subgroup of patients with Alzheimer's disease (1988) (25)
Reduced CSF CART in dementia with Lewy bodies (2009) (25)
Executive dysfunction correlates with caudate nucleus atrophy in patients with white matter changes on MRI: A subset of LADIS (2013) (25)
Pathophysiological aspects of frontotemporal dementia—emphasis on cytoskeleton proteins and autoimmunity (2001) (25)
First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study (2015) (24)
The frequency and influence of dementia risk factors in prodromal Alzheimer's disease (2017) (24)
Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson’s disease – a rCBF scintigraphy study (2007) (24)
Biochemical substrates in normal aging and Alzheimer's disease. (1990) (23)
Confusional symptomatology distinguishes early— and late- onset Alzheimer’s disease (1990) (23)
Heterogeneity of the Course of Alzheimer's Disease: A Differentiation of Subgroups (1991) (23)
Cognitive Reserve in Relation to Abeta42 in Patients Converting from MCI to Dementia – A Follow-Up Report (2009) (22)
Sahlgrenska Academy Self-reported Cognitive Impairment Questionnaire (SASCI-Q) – a research tool discriminating between subjectively cognitively impaired patients and healthy controls (2012) (22)
Converging pathways of chromogranin and amyloid metabolism in the brain. (2010) (22)
Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations (2017) (21)
Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease (2012) (21)
Calcitonin gene-related peptide and calcitonin in the CSF of patients with dementia and depression Possible disease markers (2002) (21)
Frequent mild cognitive deficits in several functional domains in elderly patients with heart failure without known cognitive disorders. (2015) (21)
Intra‐Blood-Brain‐Barrier Synthesis of Immunoglobulins in Patients with Dementia of the Alzheimer Type (1990) (21)
Occurrence of Delirium in Different Regional Brain Syndromes (1999) (20)
Potential Biological Markers for Cerebrovascular Disease (2003) (20)
Estimated intracranial volume from FreeSurfer is biased by total brain volume (2018) (20)
Differences in the use of everyday technology among persons with MCI, SCI and older adults without known cognitive impairment (2017) (20)
Do white matter hyperintensities on MRI matter clinically? (2010) (20)
Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease. (2017) (20)
Cognitive Impairment Questionnaire (CIMP‐QUEST): reported topographic symptoms in MCI and dementia (2010) (19)
T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study. (2015) (19)
Decreased Lumbar Cerebrospinal Fluid Levels of Monoamine Metabolites in Vascular Dementia (1996) (19)
Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study (2014) (19)
Prognostic Accuracy of Mild Cognitive Impairment Subtypes at Different Cut-Off Levels (2017) (19)
2001-2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease? (2011) (19)
Similar pattern of atrophy in early- and late-onset Alzheimer's disease (2018) (19)
Comorbidity of other chronic age-dependent diseases in dementia (1994) (18)
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow (2016) (18)
Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: data from NILVAD (2020) (18)
Cerebrospinal fluid 'neuronal thread protein' comes from serum by passage over the blood-brain barrier. (1995) (18)
Relationship between depressive symptomatology and the subcortical brain syndrome in dementia (2002) (17)
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease (2010) (17)
Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer’s disease patients (2019) (17)
Subject Index Vol. 11, 2000 (2000) (16)
Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD. (2020) (16)
Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease (2015) (16)
Progression from Mild to Pronounced MCI Is Not Associated with Cerebrospinal Fluid Biomarker Deviations (2011) (16)
High Prevalence of Stress and Low Prevalence of Alzheimer Disease CSF Biomarkers in a Clinical Sample with Subjective Cognitive Impairment (2016) (16)
The Combination of Dysexecutive and Amnestic Deficits Strongly Predicts Conversion to Dementia in Young Mild Cognitive Impairment Patients: A Report from the Gothenburg-Oslo MCI Study (2014) (15)
Shape abnormalities of the caudate nucleus correlate with poorer gait and balance: results from a subset of the LADIS study. (2015) (15)
Hypothalamic dysfunction in dementia. (1994) (15)
Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia (2017) (15)
Low Cerebrospinal Fluid Sulfatide Predicts Progression of White Matter Lesions – The LADIS Study (2012) (15)
Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data (2018) (14)
Relationship between mental impairment and HPA axis activity in dementia disorders. (1994) (14)
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort (2020) (14)
Monte Carlo feature selection and rule-based models to predict Alzheimer’s disease in mild cognitive impairment (2012) (14)
Protein analysis in cerebrospinal fluid. III. Relation to blood-cerebrospinal fluid barrier function for formulas for quantitative determination of intrathecal IgG production. (1993) (14)
EEG abnormalities in dementia reflect the parietal lobe syndrome (2001) (14)
Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women (2011) (13)
Altered thyroid hormone profile in patients with Alzheimer’s disease (2020) (13)
Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment (2017) (13)
Alzheimer Disease Ethics—Informed Consent and Related Issues in Clinical Trials: Results of a Survey Among the Members of the Research Ethics Committees in Sweden (2003) (13)
Current definition and classification of dementia diseases (1996) (12)
Erratum: National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards (Stroke (2006) 37, 9, (2220-2241)) (2007) (12)
Asymmetric Cerebral Blood Flow in Patients with Mild Cognitive Impairment: Possible Relationship to Further Cognitive Deterioration (2011) (12)
Cognitive medicine – a new approach in health care science (2018) (12)
Neuropsychological Test Performance Among Native and Non-Native Swedes: Second Language Effects (2020) (11)
MCI of different etiologies differ on the Cognitive Assessment Battery (2015) (11)
Biological Correlates of Clinical Subgroups of Alzheimer’s Disease (2002) (11)
The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial (2020) (11)
Longitudinal EEG Findings in Dementia Related to the Parietal Brain Syndrome and the Degree of Dementia (1998) (10)
Neurologic Motor Signs in Early and Late Onset Alzheimer's Disease (1992) (10)
Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis (2013) (10)
Intrathecal synthesis of immunoglobulin G in vascular dementia (1990) (10)
Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
Kinesin Light Chain 1 Gene Haplotypes in Three Conformational Diseases (2010) (9)
EEG findings in dementia are related to the parietal lobe syndrome. (1995) (9)
Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. (2020) (9)
Objective Measurement of the Alertness Level in Dementia (2003) (9)
Nimodipine in subcortical vascular dementia trial. (1999) (9)
Novel Progranulin Mutation Detected in 2 Patients With FTLD (2011) (9)
Differential Impact of Neurofilament Light Subunit on Cognition and Functional Outcome in Memory Clinic Patients with and without Vascular Burden. (2015) (9)
Amyotrophic lateral sclerosis: evidence for intact hepatocyte growth factor/met signalling axis. (2001) (8)
Increased Proteolytic Activity in Erythrocytes from Patients with Alzheimer's Disease (1992) (8)
Boston Naming Test automatic credits inflate scores of nonaphasic mild dementia patients (2016) (8)
Patients with Alzheimer's Disease Have Increased Levels of Insulin-like Growth Factor-I in Serum but not in Cerebrospinal Fluid. (2020) (8)
Memory in individuals with mild cognitive impairment in relation to APOE and CSF Aβ42 (2010) (8)
Long-term cognitive function among testicular cancer survivors treated with chemotherapy (2008) (8)
Prevalence of dementia and regional brain syndromes in long-standing Parkinson's disease. (1999) (8)
Replication study of plasma proteins relating to Alzheimer's pathology (2021) (8)
Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. (2006) (8)
Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies (2021) (8)
Vascular Disease, Alzheimer’s Disease Biomarkers and Cognition in Mild Cognitive Impairment: Additive or Synergetic Effects? (2011) (7)
Inter-rater Reliability of the STEP Protocol (2001) (7)
Valid and efficient manual estimates of intracranial volume from magnetic resonance images (2015) (7)
Device-Measured Sedentary Behavior, Physical Activity and Aerobic Fitness Are Independent Correlates of Cognitive Performance in Healthy Middle-Aged Adults—Results from the SCAPIS Pilot Study (2019) (7)
Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort (2021) (7)
The PPAR-α gene in Alzheimer's disease: Lack of replication of earlier association (2009) (7)
Blood Pressure Lowering With Nilvadipine in Patients With Mild‐to‐Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension (2019) (7)
Better prognostic accuracy in younger mild cognitive impairment patients with more years of education (2018) (7)
Demographically adjusted trail making test norms in a Scandinavian sample from 41 to 84 years (2020) (7)
No Association of VEGF Polymorphims with Alzheimer’s Disease (2010) (7)
Amino-Truncated-Amyloid 42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment (2005) (6)
A β dimer-containing human cerebrospinal fluid disrupts synaptic plasticity : prevention by systemic passive immunization (2009) (6)
Neurochemical Changes in Brains from Patients with Vascular Dementia (1991) (6)
Characteristic Biomarker and Cognitive Profile in Incipient Mixed Dementia (2019) (6)
Proceedings of the First Congress of the International Society for Vascular Behavioural and Cognitive Disorders (VAS-COG 2003) (2004) (5)
Ubiquitin Carboxyl-Terminal Esterase LI (UCHLI) SI8Y Polymorphism in Patients with Cataracts (2011) (5)
Is subcortical vascular dementia a clinical entity for clinical drug trials? (1999) (5)
[There is a strong evidence that professional boxing results in chronic brain damage. The more head punches during a boxer's career, the bigger is the risk]. (2005) (5)
Clinical diagnosis of Alzheimer's disease by primary care physicians and specialists (1992) (5)
Cerebrospinal Fluid Cytology in Alzheimer's Disease (1991) (5)
Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study (2015) (5)
Investigation of Intrathecal Synthesis of Immunoglobulin G in Primary Degenerative Dementia (Alzheimer's Disease) (1991) (5)
A metabolite-based machine learning approach to diagnose Alzheimer’s-type dementia in blood: Results from the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort (2019) (4)
Sedative Load in Community-Dwelling Older Adults with Mild–Moderate Alzheimer’s Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls (2020) (4)
Heterogeneity in Alzheimer’s Disease: A European View (1994) (4)
Subject Index Vol. 1, 1990 (1990) (4)
Delineation of two intracranial areas and the perpendicular intracranial width is sufficient for intracranial volume estimation (2018) (3)
Longitudinal measurements of cerebrospinal fluid biomarkers over four years in mild cognitive impairment (2012) (3)
The PPAR-alpha gene in Alzheimer's disease: lack of replication of earlier association. (2009) (3)
Antidepressant use and orthostatic hypotension in older adults living with mild‐to‐moderate Alzheimer disease (2020) (3)
Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease (2022) (3)
Intracerebral production of tumour necrosis factor-α in Alzheimer disease and vascular dementia (1998) (3)
P4-386 The effect of simvastatin treatmnt the processing of the amyloid precursor protein in patients with Alzheimer's disease (2004) (3)
[Clinical investigation of cognitive dysfunction by specialists]. (2002) (3)
Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology (2020) (3)
Latent Cognitive Profiles Differ Between Incipient Alzheimer's Disease and Dementia with Subcortical Vascular Lesions in a Memory Clinic Population. (2019) (2)
[A consensus on dementia diseases (I): Classification and investigation]. (1990) (2)
[Harmonization of dementia diagnoses--a necessary quality assurance]. (2001) (2)
PERIVENTRICULAR WHITE MATTER LOW ATTENUATION ON CT IN DEMENTIA OF THE ALZHEIMER TYPE AND VASCULAR DEMENTIA (1988) (2)
Contents Vol. 15, 2003 (2003) (2)
The biochemical aspects and CSF markers in Alzheimer's disease (1993) (2)
Higher thyroid function is associated with accelerated hippocampal volume loss in Alzheimer’s disease (2022) (2)
What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders? (2022) (2)
Stepwise comparative status analysis (STEP) - A clinical method for identifying regional brain syndromes in patients with dementia (1998) (2)
White Matter Lesion Progression in LADIS (2012) (2)
Neurochemical substrates of human aging and dementia. (1990) (2)
Cerebrospinal Fluid Sulfatide Levels Lack Diagnostic Utility in the Subcortical Small Vessel Type of Dementia. (2021) (2)
The presence of antibrain antibodies in the CSF of some Alzheimer disease patients: correlation with CSF parameters (1990) (2)
CSF biomarkers for Alzheimer's pathology and the effect size of APOE-ε4 (2013) (2)
Lack of Efficacy of Vinpocetine in Vascular Dementia (1990) (2)
[Structural brain imaging may improve diagnostics in dementia]. (2013) (2)
Testosterone associates differently with body mass index and age in serum and cerebrospinal fluid in men (2022) (1)
MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study (2018) (1)
Convergence of chromogranin and amyloid metabolism in the brain (2010) (1)
Patients with the Subcortical Small Vessel Type of Dementia Have Disturbed Cardiometabolic Risk Profile. (2020) (1)
Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia. (2020) (1)
Vascular Cognitive Impairment in Clinical Practice: Biomarkers in vascular dementia (2009) (1)
Monocyte chemo-attractant protein (MCP1) links microglia activation to predementia white matter (WM) tract integrity changes (2012) (1)
DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER’S DISEASE PROGRESSION (2018) (1)
[A consensus on dementia (II): A survey and special diagnosis]. (1990) (1)
Regression-based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults aged 49-79 and comparison with published norms. (2022) (1)
[Subtype identification in vascular dementia. An important step towards more precise diagnosis and improved treatment]. (1995) (1)
Identification of a novel deletion in the splice donor site of progranulin exon 6 (2009) (1)
P3-069: Increased CSF-BACE1 activity is associated with APOE-ϵ4 genotype in subjects with mild cognitive impairment and Alzheimer's disease (2008) (1)
EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER’S DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY (2017) (1)
S4-01-03 Beta-secretase (BACE1) as a predictor of risk in Alzheimer disease: High levels of BACE1 in cerebrospinal fluid of mild cognitive impairment (2006) (1)
Alzheimer Type Dementia — One or Several Disorders? (1990) (1)
Subject Index Vol. 14, 2002 (2002) (1)
All cognitive systems but speed and visuospatial functions reduce the effect of CSF pathology on other systems. (2012) (1)
Subject Index Vol. 6,1995 (1995) (1)
Subject Index Vol. 6,1995 (1995) (1)
Subject Index Vol. 44, 2000 (2000) (1)
Simultaneous Measurement of A (1–42), Total Tau, and Phosphorylated Tau (Thr) in Cerebrospinal Fluid by the xMAP Technology (2004) (1)
[New discoveries on Alzheimer disease: new biochemical markers can hopefully improve diagnosis]. (2000) (1)
Vascular dementia - pathogenic and clinical aspects (1989) (1)
Contents Vol. 3, 1992 (1992) (1)
Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks (2022) (1)
O1-4 Identification of a Novel Panel of CSF Biomarkers for the Early Diagnosis of Alzheimer's Disease (2005) (1)
P2-152 Novel diagnostic biomarkers of Alzheimer’s disease in human CSF (2006) (1)
Cross-national comparisons of the ADAS and CAMDEX: The european harmonisation project of instruments for dementia (euro-harpid) (2000) (1)
Vascular Dementia Nosology – Concepts and Evidence (2008) (1)
A novel ARC polymorphism is associated with reduced risk of Alzheimer's disease (2010) (1)
Different CSF biomarker patterns in incipient Alzheimer's disease and vascular dementia (2012) (0)
[Tacrine against Alzheimer disease? Still uncertain for which patients may the treatment be beneficial]. (1996) (0)
changes : the LADIS study independently of cerebral white matter decline and dementia in older people Depressive symptoms predict cognitive (2013) (0)
[Drugs and breast feeding: risks for the child exposed to drugs via breast milk]. (1985) (0)
Contents Vol. 19, 2005 (2005) (0)
Strong evidence that professional boxing leads to chronic brain damage (2005) (0)
Depressive symptoms predict cognitive impairment in nondisabled elderly with white matter changes: The LADIS study (2009) (0)
Subject Index Vol. 21, 2006 (2006) (0)
Subject Index Vol. 15, 2003 (2003) (0)
Background Evidence fromcross- sectional studies suggests a linkbetween cerebral age-relatedwhitematterchanges and depressive symptomsin older people, althoughthetemporal associationremains (2007) (0)
Automated quantification of small vessel disease brain changes on MRI predicts cognitive and functional decline (2019) (0)
Subject Index Vol 3, 1992 (1992) (0)
Self-reported cognitive function among testicular cancer survivors treated with chemotherapy (2008) (0)
950 LONG-TERM IMPAIRED LANGUAGE AND DECREASED WELL-BEING AMONG TESTICULAR CANCER SURVIVORS WHO RECEIVED CHEMOTHERAPY – RESULTS FROM SWENOTECA (2009) (0)
Reaching a Diagnosis of a Dementia Subtype (2008) (0)
29 Is there a neurochemical link between vascular dementia and Alzheimer's disease? (1996) (0)
Cerebral Small Vessel Disease: Cerebral small vessel disease: cerebrospinal fluid aspects (2014) (0)
phenotypes microduplications that show distinctive co-locating 17 p 13 . 3 microdeletions and Further molecular and clinical delineation of (0)
O-3-5 The depression-anxiety syndrome in dementia (1996) (0)
Significant elevation of plasma BACE in AD and MCI patients (2011) (0)
Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations (2017) (0)
Late Breaking News (2003) (0)
Quantitative structural MRI and CSF biomarkers in early diagnosis of Alzheimer's disease (2011) (0)
Title European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease - The substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow (2019) (0)
Being physically active is associated with improved executive function and processing speed but not memory: The LADIS study (2013) (0)
Regression‐based normative data for the Rey Auditory Verbal Learning Test in Norwegian and Swedish adults ages 40 to 80 (2020) (0)
Contents Vol. 6, 1995 (1995) (0)
Posters: Neurogenic Inflammation (2014) (0)
Contents Vol. 6, 1995 (1995) (0)
Neurofilament light as a marker of cerebrovascular disease in incipient Alzheimer’s disease and subcortical vascular dementia (2017) (0)
Contents Vol. 16, 2003 (2003) (0)
Early symptoms and signs in cognitive decline in clinical practice (2002) (0)
Significance of computerized tomography in the diagnosis of Alzheimer's disease and other dementia disorders (1991) (0)
P3-067: MRI brain atrophy and CSF biomarkers predict decline to Alzheimer's disease in mild cognitive impairment (2008) (0)
DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION (2017) (0)
[Brain clinics are needed]. (1993) (0)
P1-306 The kinesin gene KNS2 interacts with APOE and influences the risk of Sporadic Alzheimer’s disease (2006) (0)
Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer’s disease patients (2019) (0)
SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease (2014) (0)
Cerebrospinal fluid markers of microglial activation and neuroinflammation in Alzheimer's disease (2011) (0)
[Vascular cognitive impairment a spectrum of diseases]. (2009) (0)
Contents Vol. 12, 2001 (2001) (0)
Significance of cerebrospinal fluid analyses in the diagnosis of dementia disorders (1991) (0)
NEUROPSYCHOLOGY AND 99MTC-HMPAO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY FINDINGS FROM THE GOTHENBURG MCI STUDY (2019) (0)
NILVAD: AN INVESTIGATOR DRIVEN PHASE III MULTI CENTRE EUROPEAN CLINICAL TRIAL OF NILVADIPINE IN MILD TO MODERATE ALZHEIMER'S DISEASE (2016) (0)
Regression-based cognitive change norms applied in biochemically defined predementia Alzheimer's disease. (2022) (0)
Thyroid Hormones and CSF Biomarkers in Relation to Cognition in Mild Cognitive Impairment (2010) (0)
[Cognitive medicine is supported in DSM-5]. (2014) (0)
P1-370 Monitoring the biochemical aftermath of boxing by cerebrospinal fluid analyses (2006) (0)
The five‐items memory screen‐extended variant: A tool for assessing memory (2020) (0)
[It's time to see the value of near patient research]. (2016) (0)
Subject Index Vol. 16, 2003 (2003) (0)
Sahlgrenska Academy Self-reported Cognitive Impairment Questionnaire (2019) (0)
2-12-21 Dementia in Parkinson's disease partly resembles Alzheimer's disease (1997) (0)
Theapolipoprotein Eallele 84doesnotcorrelate withthenumberofsenile plaques or neurofibrillary tangles inpatients withAlzheimer's disease MikaelLanden, AnnikaThorsell, AndersWallin, KajBlennow (1996) (0)
Contents Vol. 44, 2000 (2000) (0)
Physical activity is associated with improved executive function and processing speed: The LADIS Study (2013) (0)
Discovery, identification and validation of novel cerebrospinal fluid biomarkers of Alzheimer’s disease using SELDI-TOF mass spectrometry (2005) (0)
Contents Vol. 21, 2006 (2006) (0)
[The healthcare is important for research]. (2017) (0)
Search for protein changes in Alzheimer CSF by two-dimensional gel electrophoresis with immobilized ph gradients in the first dimension (1992) (0)
[Different opinions when it comes to research ethics issues concerning patients with dementia. A questionnaire study among members of research ethics committees]. (2004) (0)
Subcortical vascular dementia: introduction and clinical picture/diagnosis (2002) (0)
[Hospital diet--a medical matter. The new dietary regime in Stockholm hospitals]. (1970) (0)
1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France (2008) (0)
MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY (2018) (0)
JAMA Paper supplement (2015) (0)
[A check list for diagnosis and basic investigation of dementia in primary health care]. (1990) (0)
[P1–291]: WITHDRAWN (2017) (0)
Re:White matter changes and late onset depression (2017) (0)
Erratum : Converging pathways of chromogranin and amyloid metabolism in the brain (Journal of Alzheimer's Disease (2010) 20:4 (1039-1048)) (2011) (0)
Subject Index Vol. 12, 2001 (2001) (0)
caused by heading in soccer No neurochemical evidence for brain injury (2007) (0)
S18Y polymorphism in Alzheimer's disease (2010) (0)
DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER\textquotesingleS DISEASE PATHOLOGY AND PROGRESSION (2017) (0)
PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER’S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT (2018) (0)
P3-198: Haplotype study of the kinesin light chain 1 gene in Alzheimer's disease (2008) (0)
Specific Aβ oligomers and the tau/Aβ42 ratio correlate in lumbar puncture CSF (2011) (0)
O3-02-03: Alteration of beta secretase (BACE1) functional candidate biomarkers in subjects with mild cognitive impairment and Alzheimer's disease (2008) (0)
Sex-specific metabolic pathways associate with Alzheimer's Disease (AD) endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery (EMIF-AD MBD) cohort (2021) (0)
Screening for differences in CSF proteins in dementia by a two-dimensional electrophoretic technique (1992) (0)
Contents Vol. 14, 2002 (2002) (0)
High risk of PTLD development in lymphoma patients undergoing allogeneic haematopoietic stem cell transplantation in BONE MARROW TRANSPLANTATION, vol 46, issue , pp S328-S328 (2011) (0)
APOE GENOTYPE AND CSF Aβ42 IN COGNITIVELY HEALTHY INDIVIDUALS (2014) (0)
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics (2018) (0)
Contents Vol. 35, 2013 (2013) (0)
Contents Vol. 43, 2017 (2017) (0)
White Matter Diffusion Tensor Imaging Changes in Subjective and Mild Cognitive Impairment (2010) (0)
[Guidelines for brain concussion in sports--how are they to be applied in boxing?]. (2007) (0)
Subject Index Vol. 19, 2005 (2005) (0)
[Cognitive medicine--field of knowledge for future specialist education]. (2008) (0)
3 Evidence in humans linking a specific amyloid-β oligomer to tau pathobiology (2012) (0)
Identification of plasma proteome signatures associated with ATN framework using SOMAscan (2020) (0)
Symposia (2007) (0)
Progressive pre-dementia cognitive impairment is predicted by baseline increase of MRI radial diffusion (2011) (0)
Proteolytic Activity is Increased in Lymphocytes from Patients with Alzheimer’s Disease (1997) (0)
DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT (2017) (0)
Contents Vol. 11, 2000 (2000) (0)
Abstract P116: Physical Fitness in Early Adulthood: A Modifiable Risk Factor for Neurological and Psychiatric Diseases (2016) (0)
Contents Vol. 1, 1990 (1990) (0)
of Vascular Cognitive Impairment Multimodal Markers of Inflammation in the Subcortical Ischemic Vascular Disease Type (2014) (0)
Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage Neuroimaging (2015) (0)
Neurodegeneration and the Gothenburg MCI study (2019) (0)
PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY (2018) (0)
PREVALENCE OF VASCULAR RISK FACTORS IN DIFFERENT STAGES OF PRODROMAL ALZHEIMER’S DISEASE AND ITS INFLUENCE ON COGNITIVE DECLINE (2016) (0)
Re:Incidental white matter hyperintensity and medicalisation of graceful ageing (2018) (0)
Patients With Mild Cognitive Impairment CSF Biomarkers and Incipient Alzheimer Disease in Supplementary material (2009) (0)
[The concept of dementia--does it enlighten or confuse?]. (1993) (0)
Blood‐brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein‐β in patients with subcortical small‐vessel disease (2022) (0)
Reply (1991) (0)
DIFFERENT CEREBROSPINAL FLUID BIOCHEMICAL PATTERNS IN PATIENTS WITH DEMENTIA WITH SUBCORTICAL WHITE MATTER LESIONS AND PURE ALZHEIMER'S DISEASE (2011) (0)
EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE (2014) (0)
An example of exceptional practice effects in the verbal domain (2015) (0)
[Alzheimer's disease. Computer tomography--a good diagnostic method?]. (1993) (0)
The ‘CSF Alzheimer’s profile’: Easily said, but what do we mean? (2013) (0)
Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease. (2023) (0)
P3-097: Prediction of progressive mild cognitive impairment using cerebrospinal fluid biomarkers: Results from the Gothenburg mild cognitive impairment study (2008) (0)
Low Serum Insulin-like Growth Factor-I Is Associated with Decline in Hippocampal Volume in Stable Mild Cognitive Impairment but not in Alzheimer’s Disease (2022) (0)
The effects of apolipoprotein genotype on the diagnostic accuracy of cerebroispinal fluid biomarkers for Alzheimer's disease (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Anders Wallin?

Anders Wallin is affiliated with the following schools:

Anders Wallin's Academic­Influence.com Rankings

Anders Wallin's Degrees

Similar Degrees You Can Earn

Why Is Anders Wallin Influential?

Anders Wallin's Published Works

Published Works

What Schools Are Affiliated With Anders Wallin?

Anders Wallin's AcademicInfluence.com Rankings